ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 524

Expansion Of DC-STAMP+ IL-17+ Cells In Bone Marrow From Psoriasis and Psoriatic Arthritis Patients

Yahui Grace Chiu1, Edward M. Schwarz2, Jamie Biear1, Debbie Campbell3, Jennifer Hossler1, Jennifer H. Anolik4, R. John Looney1 and Christopher T. Ritchlin1, 1Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 2Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 3Allergy, Immunology and Rheumatology, Univerity of Rochester, Rochester, NY, 4Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Bone marrow, diagnosis, Psoriatic arthritis and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Focal erosions in inflammatory arthritis are mediated by bone marrow (BM) derived osteoclasts (OC) that enter the joint as OC precursors (OCP) from peripheral blood. We have previously shown that DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a 7-pass transmembrane protein essential for cell-to-cell fusion during OC differentiation, is a valid biomarker of circulating OCPs. In bone marrow (BM), naive lymphocytes encounter self-antigens to establish immune tolerance and interact with OC and osteoblast progenitors. Herein, we dissected T cell, B cell and monocyte populations, compared the percentage of these cell populations between patients and healthy individuals, examined the potential of these cells in lineage differentiation, and searched for cell subsets uniquely present in BM.

Methods:

BM and PBMC collected from 2 psoriatic arthritis (PsA), 2 psoriasis (Ps) patients and 4 healthy controls (HC) were processed and purified by Ficoll gradient, stained by antibodies, and analyzed by flow cytometry. To assess differentiation potential, cells were cultured in dendritic cell (DC)-promoting, Th17-promoting, and OC-promoting media. Phagocytic activity was assessed by FITC-dextran beads.

Results:

The OCP frequency of BM and PBMC was 3,423±306 and 1,340±120 per 10e6 monocytes, respectively. Monocytes in BM differentiated into functional DC with phagocytic activity as evidenced by the intake of FITC-dextran beads. T cells in BM differentiated into Th17-like T cells (IL17A+IL23R+DC-STAMP+CCR6+) after in vitro  culture in Th-17-promoting media. Patients with both Ps and PsA had a higher percentage of DC-STAMP+IL17A+ cells in the BM (patients:11.4%, HC:2.6%) and a higher percentage of IgD+CD27+CXCR3+ memory B cells in both BM and PBMC than HC (HC/patients= 3/60 for BM and 24/69 for PBMC). Intriguingly, a novel DC-STAMP-expressing monocyte subset (DC-STAMP+CD14+CD11b+CD16-CD34–CD45 (intermediate)), composing of approximately 18% of rosette monocytes, was only present in BM but absent in PBMC.

Conclusion:

In this study, we (1) identified a novel subset of DC-STAMP+ monocytes which is uniquely present in BM but absent in PBMC; (2) showed that BM has 3-fold more OCPs than peripheral blood; (3) found that monocytes and T cells in BM can differentiate into OC/DC and Th17 cells with full effector functions; (4) identified variations in T, B, monocyte populations between PBMC and BM; (5) found that patients with Ps and PsA had a higher % of 1A2+IL17A+CD3+ T cells and IgD+CD27+CXCR3+ B cells in BM than controls.


Disclosure:

Y. G. Chiu,
None;

E. M. Schwarz,

Laget Inc.,

1,

Laget Inc.,

2,

DePuy Inc.,

2,

DePuy Inc.,

5,

Boehringer Ingelheim,

7;

J. Biear,
None;

D. Campbell,
None;

J. Hossler,
None;

J. H. Anolik,
None;

R. J. Looney,
None;

C. T. Ritchlin,

Amgen, Janssen, UCB, Abbott, Boerhinger Ingleheim, Lilly, ,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expansion-of-dc-stamp-il-17-cells-in-bone-marrow-from-psoriasis-and-psoriatic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology